

Care CEUs

Treatment of Pregnant Women with Opioid Use Disorders

1. Neonatal abstinence syndrome (NAS) can refer to the pattern of clinical findings typically associated with opioid withdrawal in newborns.

- A. True
 - B. False
-

2. Abrupt discontinuation of opioid use during pregnancy may lead to which of the following?

- A. Premature labor
 - B. Fetal distress
 - C. Miscarriage
 - D. All of the above
-

3. Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a whole-patient approach to the treatment of substance use disorders.

- A. True
 - B. False
-

4. The prescribing of methadone and buprenorphine during pregnancy is considered ?off-label.?

- A. True
 - B. False
-

5. Which of the following statements is most accurate?

- A. Induction to naltrexone does not require detoxification.
 - B. Induction to naltrexone does not require an opioid-free period.
 - C. Induction to naltrexone requires detoxification and an opioid-free period.
 - D. Naltrexone should always be administered to an individual who is engaged in opioid use.
-

6. Pharmacological treatment is the standard of care for an infant with neonatal abstinence syndrome (NAS).

- A. True
 - B. False
-

7. Which of the following statements is most accurate?

- A. Opioid agonist treatment is thought to have a severe, long-term impact on children.
 - B. Opioid agonist treatment is thought to have minimal long-term impact on children relative to harms resulting from maternal use of heroin and prescription opioids.
 - C. Pregnant women who are physically dependent on opioids should receive withdrawal management as first line therapy.
 - D. Pregnant women who are physically dependent on opioids should be encouraged to embrace abstinence as a means of treatment.
-

8. Treatment with methadone should be initiated as early as possible during pregnancy.

- A. True
 - B. False
-

9. The five-point intervention framework encourages which of the following interventions?

- A. Pre-pregnancy education
 - B. Screening pregnant women for substance use
 - C. Developmental assessment of newborns
 - D. All of the above
-

10. Which of the following statements regarding steering committees is most accurate?

- A. Steering committees facilitate necessary cabinet, council, commission, and legislative policy changes.
 - B. Steering committees are responsible for implementing policy changes at each organization.
 - C. Steering committees consist primarily of mid-management representatives.
 - D. Steering committees primarily address priorities of the collaborative initiative.
-

11. An organization has established a core team. What should be the core team's first step towards assisting pregnant women in need of MAT?

- A. Fact gathering and sharing by all team members
 - B. Engage Key Stakeholders and Establish Work Groups
 - C. Define Shared Goals
 - D. Identify Strategies and Jointly Monitor Outcomes
-

12. Which of the following services is typically offered by substance use treatment providers?

- A. Education and community awareness
 - B. Outpatient treatment
 - C. Case management
 - D. All of the above
-

13. A collaborative team can complete a Cross-System Guide to understand the strengths and opportunities for improvement in policies and practices across systems.

- A. True
 - B. False
-

14. What is the recommended frequency of administration for extended-release injectable naltrexone?

- A. Daily
 - B. Weekly
 - C. Every Other Week
 - D. Monthly
-

15. Physicians must have a board certification in addiction medicine or addiction psychiatry to prescribe naltrexone?

- A. True
 - B. False
-

16. Methadone is an opioid antagonist.

- A. True
 - B. False
-

17. Which of the following statements regarding extended-release injectable naltrexone is most accurate?

- A. The clinical use of extended-release injectable naltrexone is for detoxification.
 - B. The clinical use of extended-release injectable naltrexone is for the prevention of relapse to opioid use disorders following opioid detoxification.
 - C. The clinical use of extended-release injectable naltrexone is for the prevention of relapse to opioid use disorders before opioid detoxification.
 - D. The clinical use of extended-release injectable naltrexone is for the treatment of opioid use disorders.
-

18. Buprenorphine should be part of a comprehensive management program that includes psychosocial support.

- A. True
 - B. False
-

19. Buprenorphine is ordered for a patient. Upon examination, the patient reports being hypersensitive to naloxone. Which of the following recommendations should be made regarding buprenorphine?

- A. Administer buprenorphine as ordered.
 - B. Administer buprenorphine with methadone.
 - C. Use caution - however, the patient does not require monitoring.
 - D. Discontinue the buprenorphine.
-

20. A 30-year-old female patient is scheduled to receive extended-release injectable naltrexone. Upon examination, the patient reports she is currently using opioids. Which of the following recommendations should be made regarding the extended-release injectable naltrexone?

- A. The extended-release injectable naltrexone should be given as scheduled.
 - B. The extended-release injectable naltrexone should be given as scheduled- however, it should be administered with methadone.
 - C. The extended-release injectable naltrexone should be given as scheduled- however, it should be administered with buprenorphine.
 - D. The extended-release injectable naltrexone should not be given while the patient is concurrently using opioids.
-

21. A female patient is currently receiving extended-release injectable naltrexone. Upon a recent exam, the patient reported experiencing several signs and symptoms of acute hepatitis. Which of the following recommendations should be made regarding the extended-release injectable naltrexone?

- A. Monitor the patient for 12 hours.
 - B. Continue the extended-release injectable naltrexone.
 - C. Hold one dose of the extended-release injectable naltrexone.
 - D. Discontinue the extended-release injectable naltrexone.
-

22. Oral methadone is ordered for a female patient. The patient is currently suffering from hypercarbia. Which of the following recommendations should be made regarding the oral methadone?

- A. Administer with caution; monitor patient for 12 hours.
 - B. Administer methadone with extended-release injectable naltrexone.
 - C. Hold one dose of oral methadone.
 - D. Discontinue methadone due to contraindication.
-

23. Extended-release injectable naltrexone is ordered for a 32-year-old female patient with thrombocytopenia. Which of the following recommendations should be made regarding the extended-release injectable naltrexone?

- A. Discontinue the extended-release injectable naltrexone.

- B. Administer the extended-release injectable naltrexone with methadone.
 - C. Administer with caution; monitor patient for 12 hours.
 - D. Administer with caution; monitor patient for 24 hours.
-

24. Which of the following statements is most accurate?

- A. Patients may become sensitive to higher doses of opioids after treatment with extended-release injectable naltrexone.
 - B. Patients may become sensitive to lower doses of opioids after treatment with extended-release injectable naltrexone.
 - C. Patients may become tolerant to lower doses of opioids after treatment with extended-release injectable naltrexone.
 - D. Patients may become tolerant to higher doses of opioids after treatment with extended-release injectable naltrexone.
-

25. A 26-year-old female patient has several questions regarding the potential complications of extended-release injectable naltrexone. Which of the following counseling points should be included in the health care professional's response to the patient's questions?

- A. An overdose may not result from trying to overcome the opioid blockade effects of naltrexone.
 - B. An overdose may result from trying to overcome the opioid blockade effects of naltrexone.
 - C. Naltrexone can be taken concurrently with long-term opioid therapy.
 - D. One dose of naltrexone should be held every week if taken concurrently with long-term opioid therapy.
-

26. Buprenorphine includes a warning about somnolence that may preclude driving or operating equipment.

- A. True
 - B. False
-

27. Buprenorphine falls in which of the following FDA pregnancy categories?

- A. FDA pregnancy category A
 - B. FDA pregnancy category B
 - C. FDA pregnancy category C
 - D. FDA pregnancy category D
-

28. Mothers maintained on methadone can breastfeed if they are not abusing substances.

- A. True
 - B. False
-

29. Buprenorphine does not possess any potential for abuse.

- A. True
 - B. False
-

30. Collaborative practice can be defined as the use of 10 system linkage elements by two or more systems, agencies, or providers to improve child and family outcomes.

- A. True
 - B. False
-

31. All CHARM women who receive MAT must also receive substance use disorder counseling and nonpharmacological substance use disorder treatment.

- A. True
 - B. False
-

32. How many days prior to delivery does CHARM recognize as the most effective time period for the involvement of child welfare systems?

- A. 10 days
 - B. 20 days
 - C. 30 days
 - D. 45 days
-

Copyright © 2025 Care CEUs

Visit us at <https://www.careceus.com>